Weiwei Tan
Impact in
- Pulmonary and Respiratory Medicine top 0.2%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Brain Metastases and Treatment
- Cancer Research top 2%
- Cancer Genomics and Diagnostics
Papers in
- Pharmacology 17
- Pharmacogenetics and Drug Metabolism 17
-
- Lung Cancer Treatments and Mutations 22
- Advanced Breast Cancer Therapies 3
- Co-authors
- Keith D. Wilner (11 shared papers)Zhongzhou Shen (2 shared papers)Daniel Botelho Costa (1 shared paper)Shuchi Sumant Pandya (1 shared paper)Wee-Lee Yeo (1 shared paper)Susumu S. Kobayashi (1 shared paper)Sai‐Hong Ignatius Ou (3 shared papers)James G. Christensen (3 shared papers)
- Journals
- Annals of Oncology (3 papers)British Journal of Clinical Pharmacology (3 papers)Future Oncology (3 papers)Pharmaceutics (2 papers)ESMO Open (2 papers)
- Partner nations
- United StatesItalyJapan
In The Last Decade
Weiwei Tan
36 papers receiving 6.8k citations
Weiwei Tan's Hit Papers
Peers
Comparison fields: 5 of 95
- Pulmonary and Respiratory Medicine 4.8k
- Cancer Research 706
- Oncology 676
- Pharmacology 212
- Pathology and Forensic Medicine 256
Countries citing papers authored by Weiwei Tan
This map shows the geographic impact of Weiwei Tan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weiwei Tan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weiwei Tan more than expected).
Fields of papers citing papers by Weiwei Tan
This network shows the impact of papers produced by Weiwei Tan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weiwei Tan. The network helps show where Weiwei Tan may publish in the future.
Co-authors
The 25 scholars most cited alongside Weiwei Tan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 37 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer Hit paper breakdown → | 2010 | 3776 |
| 2 | Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer Hit paper breakdown → | 2014 | 1638 |
| 3 | CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib Hit paper breakdown → | 2011 | 523 |
| 4 | Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification Hit paper breakdown → | 2011 | 377 |
| 5 | 2010 | 218 | |
| 6 | 2010 | 51 | |
| 7 | 2014 | 49 | |
| 8 | 2015 | 48 | |
| 9 | 2016 | 46 | |
| 10 | 2014 | 38 | |
| 11 | 2005 | 34 | |
| 12 | 2019 | 34 | |
| 13 | 2015 | 30 | |
| 14 | 2021 | 26 | |
| 15 | 2016 | 23 | |
| 16 | 2016 | 17 | |
| 17 | 2023 | 15 | |
| 18 | 2019 | 12 | |
| 19 | 2020 | 12 | |
| 20 | 2022 | 10 |
About Weiwei Tan
Weiwei Tan is a scholar working on Pharmacology, Pulmonary and Respiratory Medicine, Pediatrics, Perinatology and Child Health, Molecular Biology and Statistics and Probability, having authored 37 papers that have together received 7.1k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (22 papers), Pharmacogenetics and Drug Metabolism (17 papers), Protein Degradation and Inhibitors (6 papers), Advanced Breast Cancer Therapies (3 papers), Pharmaceutical studies and practices (3 papers), Statistical Methods in Clinical Trials (2 papers), Estrogen and related hormone effects (2 papers) and Chemotherapy-induced cardiotoxicity and mitigation (1 paper). The work is most often cited by research in Pulmonary and Respiratory Medicine (4.8k citations), Cancer Research (706 citations), Oncology (676 citations), Pharmacology (212 citations) and Pathology and Forensic Medicine (256 citations). Weiwei Tan has collaborated with scholars based in United States, Italy and Japan. Frequent co-authors include Keith D. Wilner, Zhongzhou Shen, Daniel Botelho Costa, Shuchi Sumant Pandya, Wee-Lee Yeo, Susumu S. Kobayashi, Sai‐Hong Ignatius Ou, James G. Christensen, Benjamin Solomon and Eunice Lee Kwak. Their work appears in journals such as Annals of Oncology, British Journal of Clinical Pharmacology, Future Oncology, Pharmaceutics and ESMO Open.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.